Evidence method
Level · gp.fundamentals.debt_to_revenue
41.84% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TARS · Jun 30, 2026
Tarsus Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001819790-26-000064General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.34% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
35.20% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
69.41% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
2.52% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
93.03% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-11.45% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
17.83% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
7.64% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History4 statesHistory building
Period transition
What moved in the state?
- Previous
- 44.80%
- Current
- 41.84%
- Delta
- -2.96%
- Previous
- 3.59%
- Current
- 2.34%
- Delta
- -1.25%
- Previous
- -15.21%
- Current
- 35.20%
- Delta
- 50.42%
- Previous
- 106.87%
- Current
- 69.41%
- Delta
- -37.47%
- Previous
- 2.82%
- Current
- 2.52%
- Delta
- -0.30%
- Previous
- 94.20%
- Current
- 93.03%
- Delta
- -1.17%
- Previous
- -3.78%
- Current
- -11.45%
- Delta
- -7.67%
- Previous
- 13.79%
- Current
- 17.83%
- Delta
- 4.04%
- Previous
- 7.38%
- Current
- 7.64%
- Delta
- 0.26%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Biological Products, (No Diagnostic Substances) peers →Has State · Tarsus Pharmaceuticals, Inc. →Transitioned To · TARS Fundamental State →Transitioned To · TARS BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TARS CAPEX_INTENSITY_DECREASED →Transitioned To · TARS CASH_GENERATION_INCREASED →Transitioned To · TARS GROWTH_DECREASED →Transitioned To · TARS INVENTORY_PRESSURE_DECREASED →Transitioned To · TARS MARGIN_DECREASED →Transitioned To · TARS PROFITABILITY_DECREASED →Transitioned To · TARS R_AND_D_INTENSITY_INCREASED →Transitioned To · TARS SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.